Finch Therapeutics Group, Inc. (FNCH)

USD 10.71

(-3.51%)

Market Cap (In USD)

17.19 Million

Revenue (In USD)

107 Thousand

Net Income (In USD)

-74.75 Million

Avg. Volume

12.17 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.8-14.26
PE
-
EPS
-
Beta Value
1.335
ISIN
US31773D2009
CUSIP
31773D101
CIK
1733257
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Matthew P. Blischak J.D.
Employee Count
-
Website
https://www.finchtherapeutics.com
Ipo Date
2021-03-19
Details
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.